Aeropharm selects Prosonix for crystallisation

Related tags Pharmaceutical drug

German inhaled drug specialist Aeropharm will use Prosonix’ sonocrystallisation technology to develop generics in its candidate pipeline.

The Rudolstadt-headquartered firm said that Prosonix’ unique crystallisation approach produces optimally-sized active pharmaceutical ingredient (API) particles direct from solution, bypassing destructive processes like milling and micronization that are used in traditional manufacture.

Aeropharm is targeting the lucrative inhaled drug market, which is expected to be worth $38bn in 2012. In particular the firm is focused on the development of “difficult-to-make” generic products.

Related topics Ingredients Processing equipment

Related news

Show more

Related products

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Follow us


View more